Both Equillium Inc. (NASDAQ:EQ) and Surface Oncology Inc. (NASDAQ:SURF) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium Inc.	N/A	0.00	9.82M	-0.71	0.00
Surface Oncology Inc.	59.42M	2.03	6.61M	-0.54	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Equillium Inc. and Surface Oncology Inc.

Profitability

Table 2 provides us Equillium Inc. and Surface Oncology Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Equillium Inc.	0.00%	0%	0%
Surface Oncology Inc.	-11.12%	63.7%	15.3%

Liquidity

Equillium Inc. has a Current Ratio of 1.9 and a Quick Ratio of 1.9. Competitively, Surface Oncology Inc.’s Current Ratio is 6.4 and has 6.4 Quick Ratio. Surface Oncology Inc.’s better ability to pay short and long-term obligations than Equillium Inc.

Institutional & Insider Ownership

Roughly 27.1% of Equillium Inc. shares are held by institutional investors while 60.3% of Surface Oncology Inc. are owned by institutional investors. Insiders held 21.3% of Equillium Inc. shares. Comparatively, Surface Oncology Inc. has 0.3% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Equillium Inc.	13.92%	-14.33%	-51.67%	0%	0%	-7.72%
Surface Oncology Inc.	-2.58%	-27.65%	-47.41%	-54.24%	0%	-1.89%

For the past year Equillium Inc.’s stock price has bigger decline than Surface Oncology Inc.

Summary

On 8 of the 9 factors Surface Oncology Inc. beats Equillium Inc.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.